Cybrexa, Inc.
2 known investors
Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Founders & leadership
PH
Per HellsundinCo-founder, President & CEO
RB
Ranjit BindrainScientific Co-founder & Chief Scientific AdvisorOperating Partner at HighCape Capital
PG
Peter GlazerinScientific Co-founder & Chief Medical Advisor
Investors Β· 2
Competitors Β· 3
by search overlap
Exelixis47 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Bioworld40 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Solu33 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Cybrexa, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding Β· 2 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cybrexa, Inc. do?
- Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
- Who founded Cybrexa, Inc.?
- Cybrexa, Inc. was founded by Per Hellsund, Ranjit Bindra, Peter Glazer.
- Who are Cybrexa, Inc.'s investors?
- Cybrexa, Inc.'s investors include Connecticut Innovations, HighCape Capital.